Niwinas (Desmopressin Acetate)

Desmopressin acetate selectively stimulates V2 receptors in the kidney, raising cAMP and promoting aquaporin‑2 water‑channel insertion, which enhances water reabsorption. It also activates V2 receptors on endothelial cells, causing release of stored factor VIII and von Willebrand factor, thereby supporting clot formation.

The dose of Niwinas is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function and response. Dosage regimens can differ for diabetes insipidus, nocturnal enuresis, or hemostatic use, and should follow the prescriber’s instructions.

Safety data for desmopressin acetate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Niwinas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Niwinas (desmopressin acetate) is a synthetic analogue of vasopressin with higher selectivity for V2 receptors, offering a longer duration of action and fewer vasoconstrictive effects than natural vasopressin. Compared with other oral antidiuretics, it provides more predictable water‑reabsorption and additional hemostatic benefits for bleeding disorders.

Niwinas should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments to maintain stability.

Niwinas is supplied as an oral tablet that should be swallowed whole with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing relative to meals to ensure consistent absorption.

The most serious adverse events involve severe hyponatremia, which can lead to seizures, cerebral edema, or water intoxication. Patients should be monitored for sudden weight gain, headache, nausea, or confusion, and serum sodium levels should be checked regularly during therapy.

Niwinas is contraindicated in patients with existing hyponatremia, uncontrolled hypertension, or those taking other potent antidiuretic agents. Caution is also advised for individuals with severe renal impairment, uncontrolled heart failure, or a history of water‑intoxication.